Defining and using immune archetypes to classify and treat cancer
Tumours are surrounded by a host immune system that can suppress or promote tumour
growth. The tumour microenvironment (TME) has often been framed as a singular entity …
growth. The tumour microenvironment (TME) has often been framed as a singular entity …
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Immune evasion is a hallmark of cancer, enabling tumors to survive contact with the host
immune system and evade the cycle of immune recognition and destruction. Here, we …
immune system and evade the cycle of immune recognition and destruction. Here, we …
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
CK Baumgartner, H Ebrahimi-Nik, A Iracheta-Vellve… - Nature, 2023 - nature.com
Immune checkpoint blockade is effective for some patients with cancer, but most are
refractory to current immunotherapies and new approaches are needed to overcome …
refractory to current immunotherapies and new approaches are needed to overcome …
Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction
Prolonged interferon (IFN) signaling in cancer cells can promote resistance to immune
checkpoint blockade (ICB). How cancer cells retain effects of prolonged IFN stimulation to …
checkpoint blockade (ICB). How cancer cells retain effects of prolonged IFN stimulation to …
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II …
No prospective data were available prior to 2021 to inform selection between combination
BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) …
BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) …
CRISPR screens for functional interrogation of immunity
CRISPR-based technologies represent a major breakthrough in biomedical science as they
offer a powerful platform for unbiased screening and functional genomics in various fields …
offer a powerful platform for unbiased screening and functional genomics in various fields …
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
CW Wong, C Evangelou, KN Sefton, R Leshem… - Nature …, 2023 - nature.com
Resistance mechanisms to immune checkpoint blockade therapy (ICBT) limit its response
duration and magnitude. Paradoxically, Interferon γ (IFNγ), a key cytokine for cellular …
duration and magnitude. Paradoxically, Interferon γ (IFNγ), a key cytokine for cellular …
Supramolecular biomaterials for cancer immunotherapy
H Liang, Q Lu, J Yang, G Yu - Research, 2023 - spj.science.org
Cancer immunotherapy has achieved tremendous successful clinical results and obtained
historic victories in tumor treatments. However, great limitations associated with feeble …
historic victories in tumor treatments. However, great limitations associated with feeble …
Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution
K Thol, P Pawlik, N McGranahan - Genome Medicine, 2022 - Springer
Cancer development is an evolutionary process. A key selection pressure is exerted by
therapy, one of the few players in cancer evolution that can be controlled. As such, an …
therapy, one of the few players in cancer evolution that can be controlled. As such, an …
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause
immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor …
immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor …